Literature DB >> 17560286

The role of coenzyme Q10 in statin-associated myopathy: a systematic review.

Leo Marcoff1, Paul D Thompson.   

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are currently the most effective medications for reducing low-density lipoprotein cholesterol concentrations. Although generally safe, they have been associated with a variety of myopathic complaints. Statins block production of farnesyl pyrophosphate, an intermediate in the synthesis of ubiquinone or coenzyme Q10 (CoQ10). This fact, plus the role of CoQ10 in mitochondrial energy production, has prompted the hypothesis that statin-induced CoQ10 deficiency is involved in the pathogenesis of statin myopathy. We identified English language articles relating statin treatment and CoQ10 levels via a PubMed search through August 2006. Abstracts were reviewed and articles addressing the relationship between statin treatment and CoQ10 levels were examined in detail. Statin treatment reduces circulating levels of CoQ10. The effect of statin therapy on intramuscular levels of CoQ10 is not clear, and data on intramuscular CoQ10 levels in symptomatic patients with statin-associated myopathy are scarce. Mitochondrial function may be impaired by statin therapy, and this effect may be exacerbated by exercise. Supplementation can raise the circulating levels of CoQ10, but data on the effect of CoQ10 supplementation on myopathic symptoms are scarce and contradictory. We conclude that there is insufficient evidence to prove the etiologic role of CoQ10 deficiency in statin-associated myopathy and that large, well-designed clinical trials are required to address this issue. The routine use of CoQ10 cannot be recommended in statin-treated patients. Nevertheless, there are no known risks to this supplement and there is some anecdotal and preliminary trial evidence of its effectiveness. Consequently, CoQ10 can be tested in patients requiring statin treatment, who develop statin myalgia, and who cannot be satisfactorily treated with other agents. Some patients may respond, if only via a placebo effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560286     DOI: 10.1016/j.jacc.2007.02.049

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  122 in total

1.  A viewpoint on statin effects − benefits and problems.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2008

2.  Coenzyme Q10 levels are low and associated with increased mortality in post-cardiac arrest patients.

Authors:  Michael N Cocchi; Brandon Giberson; Katherine Berg; Justin D Salciccioli; Ali Naini; Catherine Buettner; Praveen Akuthota; Shiva Gautam; Michael W Donnino
Journal:  Resuscitation       Date:  2012-03-28       Impact factor: 5.262

3.  Mitohormesis: another pleiotropic effect of statins?

Authors:  James K Liao
Journal:  Eur Heart J       Date:  2011-10-06       Impact factor: 29.983

4.  Rosuvastatin and clinical outcomes in individuals who are not deemed appropriate for baseline statin therapy.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

Review 5.  The role of red yeast rice for the physician.

Authors:  Ram Y Gordon; David J Becker
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

6.  Coenzyme Q(10) and statin myalgia: what is the evidence?

Authors:  Emilie Mas; Trevor A Mori
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

7.  Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats.

Authors:  Márta Füzi; Zoltán Palicz; János Vincze; Julianna Cseri; Zita Szombathy; Ilona Kovács; Anna Oláh; Péter Szentesi; Pál Kertai; György Paragh; László Csernoch
Journal:  J Muscle Res Cell Motil       Date:  2011-11-09       Impact factor: 2.698

8.  Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

Review 9.  Clinical perspective: statins and the liver--harmful or helpful?

Authors:  James H Lewis
Journal:  Dig Dis Sci       Date:  2012-05-12       Impact factor: 3.199

Review 10.  Evidence-based and heuristic approaches for customization of care in cardiometabolic syndrome after spinal cord injury.

Authors:  Mark S Nash; Rachel E Cowan; Jochen Kressler
Journal:  J Spinal Cord Med       Date:  2012-09       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.